BioNTech's Q2 Revenue Skyrockets by 102% to €260.8M, Marking a Significant Leap Towards Oncology Innovation

BioNTech SE reports a 102% surge in Q2 2025 revenue to €260.8M, alongside strategic moves in oncology and mRNA technology, despite a net loss. The company's stock rose 1.09% premar...